Obesity or Overweight
Metabolic Diseases
3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
2100%
+ 2 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Novo NordiskBAGSVAERD DENMARK, Denmark
3 programs2
CagrilintidePhase 3Peptide1 trial
CagrilintidePhase 3Peptide1 trial
Saxenda®N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Novo NordiskCagrilintide
Novo NordiskCagrilintide
EccogeneAZD5004
Novo NordiskSaxenda®
Clinical Trials (4)
Total enrollment: 900 patients across 4 trials
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Start: Aug 2023Est. completion: Feb 2025300 patients
Phase 3Completed
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Start: Apr 2023Est. completion: Mar 2025331 patients
Phase 3Completed
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
Start: Jun 2025Est. completion: Nov 2025
Phase 1Completed
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland
Start: Dec 2021Est. completion: Apr 2022269 patients
N/ACompleted
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
9h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Application & Integration Architect
Roche
Indianapolis
5d ago
$106K - $196K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space